logo image
search icon
Orphan Drugs CDMO Market

Orphan Drugs CDMO Market Size, Share & Trends Analysis Report By Drug Type (Biologics, Non-biologics), By Therapy Type (Oncology, Neuromuscular, Respiratory, Hematology, Others), By End-User (Pharmaceutical companies, Biotechnology companies, CROs, Other End Users), By Region, And By Segment Forecasts, 2023-2031

Report ID : 2150 | Published : 2024-10-30 | Pages: 179 | Format: PDF/EXCEL

Orphan Drugs CDMO Market Size is predicted to witness a 10.9% CAGR during the forecast period for 2023-2031.

Orphan Drugs CDMO Market

Orphan drugs, also known as orphan medicines or orphan therapies, are pharmaceuticals designed to treat rare medical illnesses known as orphan diseases. These disorders often impact a small proportion of the population, making them commercially undesirable for drug companies to research and market in the absence of additional incentives. Several important drivers have influenced the Orphan Drugs CDMO (Contract Development and Manufacturing Organization) market, contributing to its growth and relevance in the pharmaceutical sector. Orphan medications are in high demand due to increased awareness and diagnosis of rare diseases. As more uncommon diseases are discovered and characterized, the demand for specialized CDMOs to support their development and manufacture grows.

However, the COVID-19 pandemic substantially impacted numerous sectors of the pharmaceutical business, particularly the CDMO (Contract Development and Manufacturing Organization) market for orphan drugs. The COVID-19 pandemic had a greater impact on specific pharmaceutical markets due to the deferral of non-life-threatening disease diagnosis and treatment. This was especially true for people suffering from uncommon diseases since various governments concentrated more financial and healthcare resources towards combating the pandemic.

Competitive Landscape

Some Major Key Players In The Orphan Drugs CDMO Market:

  • Novartis AG
  • Hoffmann-La Roche Ltd
  • Celgene,
  • Bristol-Myers Squibb Company
  • Sanofi
  • Bayer Healthcare
  • Doppel
  • Lubrizol Life Science (LLS) Health
  • Others

Market Segmentation:

The Orphan Drugs CDMO Market segmentation consists of drug type, therapy type, and end-user. As per the drug type, the market is segmented as Biologics and Non-biologics. The therapy type segment includes Oncology, Neuromuscular, Respiratory, Hematology, and Others. The end-user segment includes Pharmaceutical companies, Biotechnology companies, CROs, and Other End-users.

Based On Drug Type, The Biologics Segment Is A Major Contributor In The Orphan Drugs CDMO Market. 

The Biologics category is expected to hold a major share of the global Orphan Drugs CDMO Market in 2022 due to the overwhelming prevalence of product offers classed as biologics. According to the U.S. FDA, the organization's Office of Orphan Products Development (OOPD) has developed and marketed approximately 600 medicines and biologic products to treat uncommon illnesses since 1983. 

The Personal Care Segment Witnessed Growth At A Rapid Rate.

The personal care catagory is projected to grow at a rapid rate in the global Orphan Drugs CDMO Market. The Orphan Drugs Contract Development and Manufacture Organisation (CDMO) market assists pharmaceutical companies with orphan medication development and manufacture. The fundamental reason for the segment's dominance is that a considerable number of medications must be administered intravenously in hospitals by qualified healthcare workers.

In The Region, The North America Orphan Drugs CDMO Market Holds A Significant Revenue Share.

The North America Orphan Drugs CDMO Market is projected to record the highest market share in terms of revenue in the near future. The substantial amount spent on orphan pharmaceuticals, the large patient population, and the existence of major market players all contributed to North America's dominance in the creation of sophisticated and cutting-edge technologies. For instance, the Genetic and Rare Diseases (GARD) Information Centre estimates that there are more than 10,000 rare diseases that afflict 30 million Americans, or about 1 in 10 persons, in the U.S. This contributes to North America's dominance in the worldwide market, together with the favourable reimbursement practices in the U.S. Due to a growing patient population in the region and a large uptake of cutting-edge treatments for rare diseases, the European market is expected to grow at a significant CAGR.

Recent Developments:

  • In Aug 2021, Novartis disclosed that Sabatolimab (MBG453) has been awarded as orphan drug by the EC (European Commission) for the management of myelodysplastic syndromes (MDS). The decision was based on clinical evidence demonstrating a significant response rate in patients with high-risk MDS who received concurrent treatment with sabatolimab and hypomethylating agents (HMAs).

Orphan Drugs CDMO Market Report Scope:

Report Attribute

Specifications

Growth Rate CAGR

CAGR of 10.9% from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Drug Type, Therapy Type, End-User

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

Novartis AG, F. Hoffmann-La Roche Ltd, Celgene, Bristol-Myers Squibb Company, Sanofi, Bayer Healthcare, Doppel, Lubrizol Life Science(LLS) Health, and Others

Customization Scope

Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Orphan Drugs CDMO Market Snapshot

Chapter 4. Global Orphan Drugs CDMO Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Drug Type Estimates & Trend Analysis

5.1. By Drug Type, & Market Share, 2020 & 2031

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Drug Type:

5.2.1. Biologics

5.2.2. Non-biologics

Chapter 6. Market Segmentation 2: By Therapy Type Estimates & Trend Analysis

6.1. By Therapy Type & Market Share, 2020 & 2031

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Therapy Type:

6.2.1. Oncology

6.2.2. Neuromuscular

6.2.3. Respiratory

6.2.4. Hematology

6.2.5. Others

Chapter 7. Market Segmentation 3: By End User Estimates & Trend Analysis

7.1. By End User & Market Share, 2020 & 2031

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By End User:

7.2.1. Pharmaceutical companies

7.2.2. Biotechnology companies

7.2.3. CROs

7.2.4. Other End Users

Chapter 8. Orphan Drugs CDMO Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Orphan Drugs CDMO Market revenue (US$ Million) estimates and forecasts By Drug Type, 2019-2031

8.1.2. North America Orphan Drugs CDMO Market revenue (US$ Million) estimates and forecasts By Therapy Type, 2019-2031

8.1.3. North America Orphan Drugs CDMO Market revenue (US$ Million) estimates and forecasts By End User, 2019-2031

8.1.4. North America Orphan Drugs CDMO Market revenue (US$ Million) estimates and forecasts by country, 2019-2031

8.2. Europe

8.2.1. Europe Orphan Drugs CDMO Market revenue (US$ Million) By Drug Type, 2019-2031

8.2.2. Europe Orphan Drugs CDMO Market revenue (US$ Million) By Therapy Type, 2019-2031

8.2.3. Europe Orphan Drugs CDMO Market revenue (US$ Million) By End User, 2019-2031

8.2.4. Europe Orphan Drugs CDMO Market revenue (US$ Million) by country, 2019-2031

8.3. Asia Pacific

8.3.1. Asia Pacific Orphan Drugs CDMO Market revenue (US$ Million) By Drug Type, 2019-2031

8.3.2. Asia Pacific Orphan Drugs CDMO Market revenue (US$ Million) By Therapy Type, 2019-2031

8.3.3. Asia Pacific Orphan Drugs CDMO Market revenue (US$ Million) By End User, 2019-2031

8.3.4. Asia Pacific Orphan Drugs CDMO Market revenue (US$ Million) by country, 2019-2031

8.4. Latin America

8.4.1. Latin America Orphan Drugs CDMO Market revenue (US$ Million) By Drug Type, (US$ Million) 2019-2031

8.4.2. Latin America Orphan Drugs CDMO Market revenue (US$ Million) By Therapy Type, (US$ Million) 2019-2031

8.4.3. Latin America Orphan Drugs CDMO Market revenue (US$ Million) By End User, (US$ Million) 2019-2031

8.4.4. Latin America Orphan Drugs CDMO Market revenue (US$ Million) by country, 2019-2031

8.5. Middle East & Africa

8.5.1. Middle East & Africa Orphan Drugs CDMO Market revenue (US$ Million) By Drug Type, (US$ Million) 2019-2031

8.5.2. Middle East & Africa Orphan Drugs CDMO Market revenue (US$ Million) By Therapy Type, (US$ Million) 2019-2031

8.5.3. Middle East & Africa Orphan Drugs CDMO Market revenue (US$ Million) By End User, (US$ Million) 2019-2031

8.5.4. Middle East & Africa Orphan Drugs CDMO Market revenue (US$ Million) by country, 2019-2031

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Novartis AG

9.2.2. F. Hoffmann-La Roche Ltd

9.2.3. Celgene, Bristol-Myers Squibb Company

9.2.4. Sanofi

9.2.5. Bayer Healthcare

9.2.6. Doppel

9.2.7. Lubrizol Life Science (LLS) Health

9.2.8. Other Prominent Players

Segmentation of Orphan Drugs CDMO Market-

Orphan Drugs CDMO Market By Drug Type-

  • Biologics
  • Non-biologics

Orphan Drugs CDMO Market Seg

Orphan Drugs CDMO Market By Therapy Type-

  • Oncology
  • Neuromuscular
  • Respiratory
  • Hematology
  • Others

Orphan Drugs CDMO Market By End-User-

  • Pharmaceutical companies
  • Biotechnology companies
  • CROs
  • Other End Users

Orphan Drugs CDMO Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Orphan Drugs CDMO Market Size?

Novartis AG, F. Hoffmann-La Roche Ltd, Celgene, Bristol-Myers Squibb Company, Sanofi, Bayer Healthcare, Doppel, Lubrizol Life Science(LLS) Health, and

Drug Type, Therapy Type and End-User are the key segments of the Orphan Drugs CDMO Market

North American region is leading the market.

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach